Q2 FY24 Financial Highlights slide image

Q2 FY24 Financial Highlights

Other Markets: Key Highlights EU Steady performance in developed markets EU • Growth driven by higher LuforbecⓇ and tender sales Strong growth in Germany and UK Completed Medisol acquisition in France South Africa Brazil Emerging Markets LUPIN BRL 74 mn sales in Q2 FY24 (growth of 6% YoY) Rank 4th in reference market³ 7th largest generics player¹ Mexico Revenues of MXN 83 mn, 63% YoY decline due to impact of stock-outs Revenues of ZAR 341 mn up by 16% QoQ 4th largest generics player² Australia Philippines 33% YoY growth driven by renal and women's health New launches from SCP portfolio API + Global Institutional . • API revenues grew 7% YoY due to increase in sales of 7ACCA and Levetiracetam Global Institutional business growth driven by higher Anti-TB and ARV sales Note: 1. IQVIA MAT Sept 23 by sales 2. IQVIA Midas Sales Audit Mar-23 3. IQVIA MAT Sept-23 units 10
View entire presentation